Gamma, a startup that creates AI-generated presentations, websites, and social media posts, announced on Monday a $68 million Series B round at a $2.1 billion valuation led by Andreessen Horowitz.

The round includes a secondary raise providing early employees with liquidity, recognizing the team’s role in building Gamma’s success SAN FRANCISCO--(BUSINESS WIRE)--Gamma, the fastest-growing AI ...

The five-year-old start-up, which has just 52 employees and is profitable, is now valued at $2.1 billion by investors including Andreessen Horowitz. By Niko Gallogly As an investment banker and ...

The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome ...

The table below is a review of notable updates that occurred in August 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...

Department of Pharmaceutical Sciences, Marshall University School of Pharmacy, Huntington, WV, United States Th9 cells are a CD4 T cell subset that produces interleukin-9 (IL-9), a pleiotropic ...

The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone ...

We've all heard about the uncomfortable side effects that come with taking GLP-1 medications like Ozempic and Wegovy: upset stomach, constipation, nausea, hair loss... The list goes on. But ...

Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...